menu
    • menu

    Company profile for ImmunoBrain Checkpoint

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ImmunoBrain Checkpoint, Inc. is a biopharmaceutical company focused on developing a pipeline of novel disease-modifying immunotherapies for neurological disorders by targeting immune checkpoint pathways. IBC’s novel approach for treatment of neurodegeneration is based on years of innovative, cutting edge scientific discoveries made by Prof. Michal Schwartz (Weizmann Institute of Science, Israel).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmunoBrain CheckpointIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    Weizmann Science Park 3 Pinhas Sapir street, Ness Ziona, IL
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ibcheckpoint.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dr. Francis S. Collins Joins Immunobrain Board of Directors
    Dr. Francis S. Collins Joins Immunobrain Board of Directors

    21 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/pioneering-physician-scientist-dr-francis-s-collins-joins-immunobrain-board-of-directors-302590340.html

    PR NEWSWIRE
    21 Oct 2025
    Share Share
    ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer
    ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer

    22 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunobrain-checkpoint-appoints-dr-sanjay-keswani-as-chief-executive-officer-302039635.html

    PR NEWSWIRE
    22 Jan 2024
    Share Share
    First subjects in IBC’s Phase Ib trial receive IBC-Ab002
    First subjects in IBC’s Phase Ib trial receive IBC-Ab002

    18 May 2023

    // CLINICAL TRIALS ARENA

    https://www.clinicaltrialsarena.com/news/first-subjects-ibcs-trial-ibc-ab002/

    CLINICAL TRIALS ARENA
    18 May 2023
    Share Share
    ImmunoBrain Checkpoint Doses First Patients in Phase 1b Trial of IBC-Ab002
    ImmunoBrain Checkpoint Doses First Patients in Phase 1b Trial of IBC-Ab002

    17 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunobrain-checkpoint-doses-first-patients-in-phase-1b-clinical-trial-of-ibc-ab002-for-alzheimers-disease-301826238.html

    PR NEWSWIRE
    17 May 2023
    Share Share
    ImmunoBrain Awarded $5M for Phase 1b Alzheimer’s Disease of Anti-PD-L1 IBC-Ab002
    ImmunoBrain Awarded $5M for Phase 1b Alzheimer’s Disease of Anti-PD-L1 IBC-Ab002

    27 Aug 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/08/27/2287643/0/en/ImmunoBrain-Checkpoint-Awarded-5-Million-US-NIA-Grant-for-Phase-1b-Alzheimer-s-Disease-Proof-of-Mechanism-Study-of-Anti-PD-L1-IBC-Ab002.html

    GLOBENEWSWIRE
    27 Aug 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search